UNSPSC 51422116: Fluocortin butyl ester

This classification denotes a dermatologic agent and glucocorticoid with the molecular formula C26H35FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6N7OA9MO7O, chemically known as pregna-1,4-dien-21-oic acid, 6-fluoro-11-hydroxy-16-methyl-3,20-dioxo-, butyl ester (6.alpha.,11.beta.,16.alpha.)-, but more generally known as fluocortin butyl ester, which bears US NIH Compound Identifier 39034.

European Medicines Agency schedules fluocortin butyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07716MIG. Most nations, for tariff purposes, schedule fluocortin butyl ester under HS 29372200. SMILES: CCCCOC(=O)C(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)F)O)C)C.

UNSPSC 51422116 Fluocortin butyl ester is a Commodity code with no recent state and local procurement activity directly aligned with its nominal scope. The two most recent opportunities tagged to this code—Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023) and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026)—address pharmaceutical procurement broadly but do not reflect demand for fluocortin butyl ester, a topical corticosteroid. The Seminole County bid solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, while the Texas HHS RFI explores vendor capacity for direct contracting with manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity targets this specific active pharmaceutical ingredient.

The code shows limited relevance for business development professionals pursuing state and local contracts at this time. Recent activity under this code does not support a sustained market for fluocortin butyl ester procurement through state and local issuing bodies. Monitor the code for future opportunities, but the current posting activity suggests that state and local procurement in pharmaceutical categories gravitates toward opioid-antagonist products, drug disposal systems, and pharmacy benefit program infrastructure rather than specialty topical corticosteroids.